European CE Mark Reinstated for Endologix's Nellix EVAS System

 

June 6, 2019—Endologix, Inc. announced that CE Mark certification for the company's Nellix endovascular aneurysm sealing (EVAS) system has been reinstated by GMED, the European Union Notified Body for the device, after an assessment of clinical evidence. The Nellix system is intended for the treatment of abdominal aortic aneurysms.

In January 2019, the company announced that the CE Mark certification had been suspended in response to a voluntary recall and Field Safety Notification.

As previously disclosed, the Nellix system will be made available for use at approved centers in a postmarket clinical investigational setting outside the United States. Within the United States, the Nellix system remains an investigational device as part of the EVAS2 study.

Matt Thompson, MD, Chief Medical Officer of Endologix, stated in the announcement, “We continue to believe that the Nellix system has the potential to transform the treatment of patients with infrarenal abdominal aortic aneurysms. This therapy continues to generate positive results when used in patients that conform to the anatomical indications for use. We are delighted that the available data supports the reinstatement of our CE Mark, and we look forward to utilizing this technology to improve the patient experience and drive better outcomes.”

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.